louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03056547: Biomarkers in Dyspnea
Official title: Biomarkers in Dyspnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Sponsor class: OTHER
First posted: 2017-02-17
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: To explore biological mechanisms in human model of induced dyspnea, in order to remove the source of dyspnoea, to modify cerebral impact and to allow the development of targeted therapies.

Detailed description: The aim of the study will be to identify a specific biology and immunology associated with dyspnoea. It will open therapeutic possibilities through a better understanding of the mechanisms of dyspnea.

Healthy volunteers will underwent two types of dyspnea. The subjects will be first familiar with both types of dyspnea and dyspnea measurement scales. Different components of dyspnea will be measured.

Blood tests will be performed at different times (before dyspnea, during dyspnea, 60 and 90 min after dyspnea)

Eligibility criteria: Inclusion Criteria:

* healthy volunteers

Exclusion Criteria:

* pregnancy
* ongoing pain
* respiratory disease
* high levels of depression, panic disorder, or other significant mental health problems
* not fluent in french

Primary outcomes:
measure: Biomakers in dyspnea
timeFrame: 60 minutes
Secondary outcomes:
measure: Correlation with dyspnea intensity
timeFrame: 60 minutes
measure: Correlation with dyspnea type
timeFrame: 60 minutes
Other outcomes:
Locations:
city: Paris
country: France
facility: Centre d'Investigation Clinique Paris Est - Groupe Hospitalier Pitié-Salpêtrière
Study officials:
References:
Clinical trial NCT04041947: Delirium Assessment in the Pediatric Intensive Care Unit
Official title: Assessment of Delirium Frequency and Risk Factors in Pediatric Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Delirium
Keywords: Delirium
Pediatric intensive care
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2019-08-01
Enrollment: 140
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children in PICU

Brief summary: The aim of this study was to show the efficacy of non-pharmacological interventions on preventing pediatric delirium in pediatric intensive care unit

Detailed description: The aim of this study was to show the efficacy of non-pharmacological interventions on preventing pediatric delirium in pediatric intensive care unit. Patients who is followed up for at least 48 hours in pediatric intensive care unit will be included in the study. Parents of patients will be allowed to stay with the patient as long as the conditions of service is appropriate. Parents will provide oral treatments to the patients. Patients will be allowed to spend time with their phone, tablet or toy in accordance with their age. Fellow resident will screen for pediatric delirium each child using the Cornell Assessment of Pediatric Delirium twice a day.

Eligibility criteria: Inclusion Criteria:

* Pediatric Cerebral Performance Category \< 5 points
* Patients who stay in PICU \>48 hours

Exclusion Criteria:

* Pediatric Cerebral Performance Category \> 4 points
* Patients who stay in PICU \<48 hours

Primary outcomes:
measure: Pediatric delirium frequency
timeFrame: Up to a month
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Cukurova University Medicine Faculty
Study officials:
affiliation: Cukurova University Medicine Faculty
name: Dinçer Yildizdaş, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT04834947: Hemodynamic Effect of Prone Position in Non-intubated Patient With COVID 19
Official title: Hemodynamic Effect of Prone Positioning in Non-intubated Patient With COVID 19 Pneumonia: a Monocentric Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Pneumonia, Viral
Keywords: COVID 19
prone position
hemodynamic effect
spontaneous ventilation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients scheduled for cadiac surgery wih cardiopulmonary bypass

Brief summary: Prone position in non-intubated patient has shown some respiratory physiological benefits. Prone positioning in patient intubated with ARDS has shown hemodynamic benefits. We aim to compare hemodynamic assessment before and after prone positioning in non-intubated patient with COVID 19 pneumonia. The study hypothesis is that prone positioning in non-intubated patient improve right ventricular preload, reduce afterload and increase Cardiac index compared to supine position.


Eligibility criteria: Inclusion Criteria:

* Adult patient
* COVID 19 pneumonias with Hypoxemia
* for whom prone positioning has been decided by the attending physician.

Exclusion Criteria:

* Mechanical ventilation
* ECLS

Primary outcomes:
measure: Hemodynamic effect
timeFrame: Cardiac index will be recorded before, just after prone position and after return to supine position.
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Service d'Anesthésie-Réanimation, Hôpital Louis Pradel,
Study officials:
References:
Clinical trial NCT04366947: Intravascular Access in Suspected/Confirmed COVID-19 Patient
Official title: Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emergency Medicine
Cardiopulmonary Arrest
Shock
Keywords: intravascular access
intraosseous access
personal protective equipment
cardiopulmonary resuscitation
shock
Lead sponsor: Lazarski University
Sponsor class: OTHER
Collaborators: name: Poznan University of Medical Sciences
name: Medical University of Bialystok
name: Wroclaw Medical University
First posted: 2020-04-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.


Eligibility criteria: Inclusion Criteria:

* Out-of-hospital cardiac arrest (OHCA)
* Adult ≥ 18 years old
* Non-traumatic cause of cardiac arrest

Exclusion Criteria:

* Existing do-not-attempt-resuscitation order
* OHCA patients with contraindications to IO access or IV access
* Patients with signs of obvious death, e.g. rigor mortis

Primary outcomes:
measure: Success rate of first intravascular access attempt
timeFrame: 1 day
Secondary outcomes:
measure: time to successful access
timeFrame: 1 day
measure: number of attempts to successful access
timeFrame: 1 day
measure: time to infusion
timeFrame: 1 day
measure: complication rates
timeFrame: 1 day
measure: ROSC
timeFrame: 1 day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Lazarsku University
state: Masovian
Study officials:
affiliation: Lazarski University
name: Lukasz Szarpak, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05019547: The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Official title: Validity and Reliability of the Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Axial Spondyloarthritis
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2021-08-25
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Axial Spondyloarthritis

Brief summary: Our aim in this study is to translate the Inflammatory Arthritis Facilitators and Barriers to Physical Activity (IFAB) Questionnaire which was developed to determine the factors that facilitate and prevent individuals for physical activity for patients with inflammatory arthritis into Turkish language. Also, our aim is to evaluate the validity and reliability of the IFAB Questionnaire in the Turkish population, and to perform a cultural adaptation if necessary at the same time. Determining the factors that facilitate and prevent individuals for physical activity interventions with rheumatic diseases and then designing physical activity programs considering these factors may play an important role in reducing the symptoms caused by the disease and increasing their quality of life.


Eligibility criteria: Inclusion Criteria:

* Being 18 years or older,
* Diagnosed with Axial Spondyloarthritis by an experienced rheumatologist
* To have the neurological competence and cognitive level to answer the scale questions.

Exclusion Criteria:

* Having a rheumatological disease other than Axial Spondyloarthritis ,
* Using an assistive device for walking.
* Any verbal or written communication problems in Turkish,

Primary outcomes:
measure: Inflammatory Arthritis Barriers and Facilitators to Physical Activity Questionnaire (IFAB)
timeFrame: 1 day
measure: The Exercise Benefits or Barriers Scale
timeFrame: 1 day
measure: International Physical Activity Questionnaire - Short Form
timeFrame: 1 day
Secondary outcomes:
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: 1 day
measure: Health Assessment Questionnaire - Disability Index
timeFrame: 1 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Haydarpasa Numune Research and Training Hospital
Study officials:
References:
Clinical trial NCT01032447: Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Official title: Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Genital Neoplasms, Female
Gynecologic Cancers
Breast Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2009-12-15
Enrollment: 45
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: diagnosis of any gynecologic or breast cancer and be pursuing treatment here at Stanford within the last 2 years

Brief summary: Pilot study for assessing the effectiveness of a Navigator program to aid in clinical trial participation amongst the Chinese demographic


Eligibility criteria: Inclusion Criteria:

Cancer patients for Focus Group must meet the following criterion:

* diagnosis of any gynecologic or breast cancer and be pursuing treatment here at Stanford within the last 2 years
* must read and speak Chinese
* willing and able to participant in group discussions

Cancer patients to receive Navigator Support must meet the following criterion:

* Newly diagnosed with gynecologic or breast cancer -pursuing treatment at Stanford Cancer Center
* must read and speak Chinese
* willing and able to have an individual relationship with a Navigator

Health Professional must meet the following criterion:

-must currently work in the Stanford gynecologic Oncology Clinic

Navigators must meet the following criterion:

* Chinese and English speaking
* willing and able to participate in training and to serve as a Navigator
* preferably a Cancer survivor

Exclusion Criteria:

Cancer patients must have a GOG performance status of 0-2 (see attached document for further details). Focus Group participate MAY be able to be participating in another study but patients who are already participating in a clinical trial will not be assigned a Navigator.

No Exclusionary criterion for Health Professionals or Navigators.

Primary outcomes:
measure: feasibility of the program
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Nelson N Teng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04382547: Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Official title: Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: COVID
Covid-19
Coronavirus
Pneumonia
Pneumonia, Viral
Pneumonia, Interstitial
Sars-CoV2
Keywords: pneumonia
Sars-COV2
Covid-19
Lead sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Sponsor class: OTHER_GOV
Collaborators: name: Belarusian State Medical University
First posted: 2020-05-11
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Detailed description: During the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. The positive outlook for the effectiveness of MSCs is due to the following:

* knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs;
* high tropism of MSCs to lung tissue when administered intravenously;
* the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure;
* positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.

Eligibility criteria: Inclusion Criteria:

* PCR-confirmed Covid-19 pneumonia
* respiratory failure

Exclusion Criteria:

* diagnosed cancer

Primary outcomes:
measure: Number of cured patients
timeFrame: 3 weeks
Secondary outcomes:
measure: Number of patients with treatment-related adverse events
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Minsk
country: Belarus
facility: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Study officials:
affiliation: Director, the Institute of Biophysics and Cell Engineering of NAS of Belarus
name: Andrei Y Hancharou, Dr.
role: STUDY_DIRECTOR
affiliation: Head of the chair, Belarusian State Medical University
name: Eduard A Dotsenko, Dr., prof.
role: STUDY_DIRECTOR
affiliation: Head of the Lab of Institute of Biophysics and Cell Engineering of NAS
name: Natalia G Antonevich, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05040347: Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma
Official title: Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neutrophil Extracellular Trap Formation
Portal Vein Tumor Thrombosis
Keywords: Neutrophil Extracellular Trap
Portal Vein Tumor Thrombosis
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2021-09-10
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Eighty-six patients with patients treated at the Affiliated Hospital of Qingdao University (China) from September 2020 to January 2021 were recruited for this study, including 14 patients with portal vein tumor thrombosis, 28 patients without portal vein tumor thrombosis and 44 patients without hepatocellular carcinoma.

Brief summary: The aim of this study was to investigate whether NETs markers can enhance predict portal vein tumor thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.

Detailed description: Eighty-six patients with patients treated at the Affiliated Hospital of Qingdao University (China) from September 2020 to January 2021 were recruited for this study, including 14 patients with portal vein tumor thrombosis, 28 patients without portal vein tumor thrombosis and 44 patients without hepatocellular carcinoma. NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits. T-test was performed to analyze whether there was a statistical difference between the two groups, and regression analysis was performed between NETs markers and tissue factor and anti-β2 glycoprotein I to investigate whether there was a correlation. This study without any intervention measures, will not cause harm.

Eligibility criteria: Inclusion Criteria:

（1) Clinical diagnosis of HCC with liver cirhosis (2) Clinical diagnosis of portal vein tumor thrombosis

Exclusion Criteria:

(1) secondary liver malignancy (2)hematologic diseases (3) Bud-Chiah syndrome (4) incomplete data

Primary outcomes:
measure: Concentration of NETs markers and anti-β2 glycoprotein I
timeFrame: 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Qingdao
country: China
facility: the Affiliated Hospital of Qingdao University
state: Shandong
Study officials:
References:
Clinical trial NCT01822847: Physiological Response of Cortisol to Cardiac Catheterization
Official title: Physiological Response of Cortisol to Cardiac Catheterization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adrenal Insufficiency
Keywords: adrenal
steroids
cortisol
stress
Lead sponsor: Creighton University
Sponsor class: OTHER
First posted: 2013-04-02
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 males and females, age 20-90 years who are scheduled for elective cardiac catheterization procedure.

Brief summary: Cortisol is essential for survival. The importance of cortisol response is most apparent in patients with partial or complete deficiency of glucocorticoids during stressful events such as illness or surgery.

Detailed description: It is known that cortisol and other stress hormones increase during acute myocardial infarction as well (9-11). Cardiac catheterization is an essential tool for the management of acute coronary syndrome, and for the evaluation of the burden of coronary artery disease in cardiac patients.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing elective cardiac catheterization, who are willing and able to give consent.

Exclusion Criteria:

* • Patients with .primary or secondary adrenal insufficiency.

  * Patients taking steroids in the doses equivalent of at least 5 mg of prednisone daily for more than 3 weeks in the previous year.
  * Patients undergoing cardiac catheterization in the setting of acute coronary syndrome, eg. STEMI, NSTEMI and unstable angina.
  * Patients with low albumin level (\<3.5 g/dL)

Primary outcomes:
measure: cortisol change
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
Study officials:
affiliation: Creighton University
name: Valentina Tarasova, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06467747: The Efficacy of Music on Perioperative Pain Management
Official title: The Efficacy of Intraoperative Music Stimulation on Perioperative Pain Management
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Perioperative Pain Management
Keywords: Music therapy
Lead sponsor: Taichung Tzu Chi Hospital
Sponsor class: OTHER
First posted: 2024-06-21
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if intraoperative music stimulation works to alleviate perioperative pain in surgical patients undergoing general anesthesia. It will also learn about the possible mechanisms by how music affects pain.

The main questions it aims to answer are:

Does music lower the number of times participants need to use a rescue analgesic? What changes occur in electroencephalogram (EEG) and nociception monitors when participants listen to music? Researchers will compare music to mute or control (hear ambient sounds without earphones) to see if music works to alleviate perioperative pain.

Participants will listen music or mute or ambient sounds throughout the operation, and receive routine anesthesia care.


Eligibility criteria: Inclusion Criteria:

* Older than 20 years old and younger than 80 years old
* male or female
* Scheduled for minimally invasive surgery (laparoscopic cholecystectomy, appendectomy)
* Ambulatory surgery
* American Society of Anesthesiologists (ASA) physical status I\~III

Exclusion Criteria:

* Severe hearing impairment
* Severe pulmonary or cardiovascular disease
* Brain or central nervous system (CNS) disorder
* Long-term systemic steroid or daily morphine treatment
* Pregnant women
* Emergency surgery
* The absence of informed consent

Primary outcomes:
measure: Numeric Rating Scale (NRS)
timeFrame: 1. While in the post-anesthesia care unit, for an average of 1 hour. 2. 24 hours after surgery.
Secondary outcomes:
measure: Analgesic-frequency
timeFrame: 1. During the operation. 2. While in the post-anesthesia care unit, for an average of 1 hour. 3. 24 hours after surgery.
measure: Analgesic-total amount
timeFrame: 1. During the operation. 2. While in the post-anesthesia care unit, for an average of 1 hour. 3. 24 hours after surgery.
measure: Post-operative nausea and vomiting (PONV)
timeFrame: 1. While in the post-anesthesia care unit, for an average of 1 hour.
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
state: Not In USA
Study officials:
affiliation: Taichung Tzu Chi Hospital
name: Mei-Ling Shen
role: PRINCIPAL_INVESTIGATOR
References: